Study Evaluating Prevenar in High-Risk Children
NCT00234338 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 5000
Last updated 2007-12-10
Summary
The purpose of this study is to estimate the local and systemic tolerability of Prevenar in children ages 2 to 5 years old in usual care settings.
Conditions
- Pneumococcal Disease
Sponsors & Collaborators
-
Wyeth is now a wholly owned subsidiary of Pfizer
lead INDUSTRY
Principal Investigators
-
Medical Monitor · Wyeth is now a wholly owned subsidiary of Pfizer
-
Trial Manager · For Germany, [email protected]
Eligibility
- Min Age
- 2 Years
- Max Age
- 5 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2005-10-31
- Completion
- 2007-04-30
Countries
- Germany
Study Locations
More Related Trials
-
Study Evaluating Prevenar in the Prevention of Invasive Pneumococcal Disease (IPD) in the Paediatric Population in Spain.
NCT00227188 ·Status: COMPLETED
-
Prevenar (13v) Infant Drug Use Investigation
NCT02119104 ·Status: COMPLETED
-
Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.
NCT00366340 ·Status: COMPLETED ·Phase: PHASE3
-
Immunogenicity and Safety Study of Pneumococcal 7-Valent Conjugate Vaccine in Sickle Cell Disease Infants.
NCT00368186 ·Status: TERMINATED ·Phase: PHASE4
-
Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants
NCT00384059 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.
NCT00368966 ·Status: COMPLETED ·Phase: PHASE3
-
Prevenar (PCV-7) Post-Licensure Safety Study In Russia
NCT01207583 ·Status: COMPLETED
-
Study Evaluating Pneumococcal Meningitis in the Paediatric Population in Spain Four Years After the Marketing of Prevenar.
NCT00227214 ·Status: COMPLETED
-
Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants
NCT00366678 ·Status: COMPLETED ·Phase: PHASE3
-
Post-Marketing Study of the Safety of Prevenar (Pneumococcal Conjugate Vaccine, 7-valent)
NCT00683410 ·Status: COMPLETED
-
Study Estimating the Impact of Prevnar 13™ (13vPnC) on Invasive Pneumococcal Disease
NCT01128439 ·Status: COMPLETED
-
Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants
NCT00474539 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine.
NCT00370396 ·Status: COMPLETED ·Phase: PHASE3
-
Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine in Healthy Infants
NCT03512288 ·Status: COMPLETED ·Phase: PHASE2
-
Prevenar Special Use-result Surveillance in Japan (Regulatory PostMarketing Commitment Plan)
NCT01521897 ·Status: COMPLETED
-
Assessment of Antibody Persistence in Children Previously Vaccinated With Pneumococcal Conjugate Vaccine
NCT00624819 ·Status: COMPLETED ·Phase: PHASE3
-
Study Investigating Administration of Prevenar for Post-Marketing Surveillance
NCT00195390 ·Status: COMPLETED
-
Prevenar13 Post Market Surveillance
NCT01509105 ·Status: COMPLETED
-
Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants
NCT00366899 ·Status: COMPLETED ·Phase: PHASE3
-
Study Evaluating Streptococcus Pneumoniae Nasopharyngeal Carriage Rate in Children Receiving Prevnar®
NCT00488371 ·Status: COMPLETED
-
A Study To Assess The Safety And Effectiveness Of Prevenar In Chinese Children Who Have Not Previously Received A Vaccine Against Pneumococcal Bacteria
NCT01193582 ·Status: COMPLETED ·Phase: PHASE4
-
Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Preterm Compared to Term Infants.
NCT01193335 ·Status: COMPLETED ·Phase: PHASE4
-
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Healthy Children Aged 15 Months to 17 Years
NCT00761631 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Learn About the Safety of PREVENAR 20 Vaccine in Infants Aged Between Two to Six Months
NCT06622109 ·Status: ACTIVE_NOT_RECRUITING
-
Wyeth Study To Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants
NCT00464945 ·Status: COMPLETED ·Phase: PHASE3